Check out this morning’s top movers from around Wall Street, compiled by The Fly.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
HIGHER –
- Vaxcyte (PCVX) up 34% after posting positive topline data from a Phase 1/2 study of VAX-31, the company’s 31-valent pneumococcal conjugate vaccine PCV candidate designed to prevent invasive pneumococcal disease
- Unity (U) up 7% after Morgan Stanley upgraded the stock to Overweight from Equal Weight, saying it now views forward estimates as “derisked”
- Illumina (ILMN) up 1% after the European Court of Justice agreed with the company’s claim that the European Commission had no grounds to scrutinize its $8B acquisition of cancer screening start-up GRAIL in 2021
DOWN AFTER EARNINGS –
LOWER –
- Boeing (BA) down 4% after Wells Fargo downgraded the stock to Underweight, saying it sees the company’s free cash flow peaking by 2027 as aircraft development costs offset further production growth
- Dyne Therapeutics (DYN) down 32% after saying Chief Medical Officer Wildon Farwell is stepping down from the role
- U.S. Steel (X) down 4% after Vice President Kamala Harris said the company should remain domestically owned and operated, opposing Nippon Steel’s (NPSCY) pending purchase
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCVX:
- Vaxcyte’s VAX-31 Shows Promise in Pneumococcal Disease Trial
- Vaxcyte reports data from study of VAX-31 vaccine candidate in adults 50+
- Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
- Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
- Vaxcyte reports Q2 EPS ($1.10), consensus (98c)
